Toxicity and patient-reported quality of life through 12 months following pelvis-inclusive once-weekly stereotactic body radiotherapy versus conventional IMRT for high-risk prostate cancer: updated results of the SRAM randomized phase II trial
Toxicity and patient-reported quality of life through 12 months following pelvis-inclusive once-weekly stereotactic body radiotherapy versus conventional IMRT for high-risk prostate cancer: updated results of the SRAM randomized phase II trial. // Radiotherapy & Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0167814026045391?dgcid=rss_sd_all
Toxicity and patient-reported quality of life through 12 months following pelvis-inclusive once-weekly stereotactic body radiotherapy versus conventional IMRT for high-risk prostate cancer: updated results of the SRAM randomized phase II trial. Radiotherapy & Oncology. https://www.sciencedirect.com/science/article/pii/S0167814026045391?dgcid=rss_sd_all
“Toxicity and patient-reported quality of life through 12 months following pelvis-inclusive once-weekly stereotactic body radiotherapy versus conventional IMRT for high-risk prostate cancer: updated results of the SRAM randomized phase II trial.” Radiotherapy & Oncology.
@article{article63723,
title = {Toxicity and patient-reported quality of life through 12 months following pelvis-inclusive once-weekly stereotactic body radiotherapy versus conventional IMRT for high-risk prostate cancer: updated results of the SRAM randomized phase II trial},
journal = {Radiotherapy \& Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0167814026045391?dgcid=rss_sd_all}
}